Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals Inc (NQ: AMRX )

8.235 +0.195 (+2.43%)
Streaming Delayed Price Updated: 2:31 PM EDT, Aug 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 827,399
Open 7.940
Bid (Size) 8.230 (46)
Ask (Size) 8.240 (49)
Prev. Close 8.040
Today's Range 7.940 - 8.240
52wk Range 5.010 - 8.150
Shares Outstanding 1,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
AMRX stock results show that Amneal Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Amneal Reports Second Quarter 2024 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+37.71%
+37.71%
1 Month
+13.74%
+13.74%
3 Month
+22.36%
+22.36%
6 Month
+42.47%
+42.47%
1 Year
+32.61%
+32.61%

More News

Read More
Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report Second Quarter 2024 Results on August 9, 2024
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
From Kashiv BioSciences, LLC
Via Business Wire
Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Releases 2023 Environmental, Social and Governance Report
From Amneal Pharmaceuticals, Inc.
Via Business Wire
3 Stocks to Buy That Are Up 100% Over the Past 52 Weeks
Via InvestorPlace
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.